Diagnosis and treatment of Alzheimer´s and other neurodementing dseases
A-beta-autoantibodies were isolated from the serum of Alzheimer patients. The cDNA and amino acid sequences of the variable regions of the heavy and the light chains were determined and all possible pairings of the chains were expressed in mammalian cells.<br>
A number of these pairings were found to bind with higher affinity to A-beta dimers than to A-beta monomers. One of these was shown to possess biological activities potentially useful for the treatment of Alzheimer´s disease.<br> Consensus sequences were determined and used to prepare human anti-beta-amyloid antibodies useful for preventing or treating neurodementing diseases like Alzheimer´s. These human anti-beta-amyloid antibodies are suitable for detecting and measuring the progression of neurodementing disease and methods are provided for delaying the onset or progression of these diseases.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Combatting disruptive ‘noise’ in quantum communication
In a significant milestone for quantum communication technology, an experiment has demonstrated how networks can be leveraged to combat disruptive ‘noise’ in quantum communications. The international effort led by researchers…
Stretchable quantum dot display
Intrinsically stretchable quantum dot-based light-emitting diodes achieved record-breaking performance. A team of South Korean scientists led by Professor KIM Dae-Hyeong of the Center for Nanoparticle Research within the Institute for…
Internet can achieve quantum speed with light saved as sound
Researchers at the University of Copenhagen’s Niels Bohr Institute have developed a new way to create quantum memory: A small drum can store data sent with light in its sonic…
